New combo therapy shows promise for aggressive breast cancer in early trial
NCT ID NCT06817525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (Camrelizumab) given before surgery can eliminate all cancer in patients with early triple-negative breast cancer. About 64 participants will receive this treatment to see how many achieve a complete response (no cancer left at surgery). The goal is to find a more effective approach for this aggressive cancer type.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan cancer hospital
RECRUITINGZhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?